Role of the Renin-angiotensin-aldosterone System and Proinflammatory Mediators in Cardiovascular Disease.
From: Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. cferrari@wfubmc.edu
The American journal of cardiology
- Publish Date: Jul 2006
- ISSN: 0002-9149
- Volume: 98
- Issue: 1
- Pages: 121-8
- Medium: Print
- Language: English
- Citation (JAMA): Ferrario Carlos M, Strawn William B, et al. Role of the Renin-angiotensin-aldosterone System and Proinflammatory Mediators in Cardiovascular Disease.. Am. J. Cardiol. Jul 2006;98:121-8
Abstract
Inflammation is a key mechanism in the initiation, progression, and clinical sequelae of cardiovascular diseases (CVDs), including atherosclerosis, nephropathy, and cardiomyopathy. Angiotensin II, the major effector peptide of the renin-angiotensin-aldosterone system (RAAS), plays a significant role in the advent and perpetuation of these inflammatory diseases, most notably in atherogenesis. Consequently, suppression of the influence of angiotensin II by angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers may reduce or potentially reverse atherosclerosis and other inflammation-associated CVDs. Angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors exert anti-inflammatory actions and prevent or reduce the development of atherosclerosis in animal models. Clinically, RAAS suppression reduces common carotid and femoral artery intima-media thickness, thus indicating moderation of the vascular disease process. These clinical benefits likely involve restraint of the deleterious effects of angiotensin II in addition to, or independent of, lowering blood pressure. Increasing evidence that the detection and monitoring of vascular inflammation are important tools in the management of atherosclerosis also implicates the RAAS in this pathogenic process. Inflammatory molecules such as intercellular adhesion molecule-1, vascular cell adhesion molecule-1, monocyte chemoattractant protein-1, tumor necrosis factor-alpha, and C-reactive protein have potential diagnostic and prognostic values in CVD and are modified by angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. Monitoring these markers may be crucial for determining which agents, or combinations of agents, will result in the most clinically beneficial outcomes for patients. Large-scale trials are still required to determine the effects of the long-term suppression of inflammation on CVDs through the use of RAAS modulating agents, as well as to determine how closely markers of inflammatory activity may correlate with CVD outcomes.
Mesh Headings (Keywords): Angiotensin II, Angiotensin-Converting Enzyme Inhibitors, Atherosclerosis, Biological Markers, Blood Pressure, C-Reactive Protein, Cardiovascular Diseases, E-Selectin, Humans, Inflammation, Intercellular Adhesion Molecule-1, Interleukins, Renin-Angiotensin System, Tumor Necrosis Factor-alpha
Check for Full Text / PubMed Unique Identifier (PMID): 16784934
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.